by VICO Therapeutics | Jul 29, 2021 | Press Release
Leiden, The Netherlands, 29 July 2021 – VICO Therapeutics,a Leiden Bio Science Park, the Netherlands, based biotech company focusing on the development of RNA modulating therapies for rare neurological disorders, today announced that the Office of Orphan...
by VICO Therapeutics | Jun 29, 2021 | Press Release
Leiden, The Netherlands, 29 June 2021 – VICO Therapeutics,a Leiden, the Netherlands, based biotech company focusing on the development of RNA modulating therapies for rare neurological disorders, today announced that the Office of Orphan Products...
by VICO Therapeutics | Feb 28, 2021 | Rare Disease Day
As a friend of Rare Disease Day and to show our support in their continuous quest to raise awareness amongst the general public and decision-makers about rare diseases and their impact on patients’ lives, VICO Therapeutics together with BioPartner Leiden lit up...
by VICO Therapeutics | Feb 10, 2021 | Press Release
Leiden, The Netherlands, 10 February 2021 – VICO Therapeutics, a Leiden, the Netherlands, based biotech company focusing on the development of RNA modulating therapies for rare neurological disorders, today announced that the European Commission (EC) has granted...
by VICO Therapeutics | Jul 29, 2020 | Press Release
AON-platform with focus on therapies nearing phase I trials for forms of Spinocerebellar Ataxia and Huntington Disease Other early discovery stage RNA editing platform focuses on RETT syndrome Funding led by LSP, co-led by Kurma Partners, supported by Pontifax, Droia...
